The announcement of a phase 2b trial for petrelintide indicates progress in Zealand Pharma's drug development pipeline, which is likely to be viewed positively by investors. The trial's initiation in Q4 2024 suggests a clear timeline for the drug's advancement, potentially boosting investor confidence and interest in the company's future prospects.